David O'Malley, MD

Articles

Dr. O’Malley on the Results of the KEYNOTE-775 Trial in Endometrial Cancer

April 15th 2021

David M. O'Malley, MD, discusses the results of the phase 3 KEYNOTE-775 trial in advanced endometrial cancer.

Dr. O’Malley on the Safety Profile of Mirvetuximab in Ovarian Cancer

September 3rd 2020

David O'Malley, MD, discusses the adverse effects associated with mirvetuximab soravtansine in ovarian cancer.

Dr. O’Malley on the Activity of Mirvetuximab Soravtansine in Ovarian Cancer

July 21st 2020

David O'Malley, MD, discusses the activity of ​the investigational antibody-drug conjugate mirvetuximab soravtansine in ovarian cancer.

Dr. O’Malley on the Utility of Mirvetuximab in Ovarian Cancer

June 24th 2020

David O'Malley, MD, discusses the utility of mirvetuximab soravtansine in ovarian cancer.

Dr. O'Malley on Antitumor Activity With Veliparib Combo in Serous Ovarian Cancer

April 22nd 2020

David O'Malley, MD, discusses antitumor activity with veliparib in combination with chemotherapy in patients with high grade serous ovarian cancer.

Dr. O'Malley on Increased Benefit of Rucaparib Maintenance in RAD51C/D-Mutant Ovarian Cancer

April 10th 2020

David O'Malley, MD, discusses the increased benefit of rucaparib maintenance in patients with ovarian cancer who express RAD51C/D mutations.

Dr. O'Malley on Maintenance Rucaparib in Non-BRCA HRR-Mutated Ovarian Cancer

April 9th 2020

David O’Malley, MD, discusses the rationale to evaluate the clinical benefit of rucaparib maintenance treatment following disease progression in a subgroup of patients with ovarian cancer whose disease is associated with a mutation in a non-BRCA homologous recombination gene in the phase III ARIEL3 trial in ovarian cancer.

Dr. O'Malley on Research With Immunotherapy in Ovarian Cancer

April 8th 2020

David O’Malley, MD, discusses the current state of immunotherapy in ovarian cancer.

Dr. O'Malley on the State of Immunotherapy in Ovarian Cancer

March 26th 2020

David O’Malley, MD, discusses the state of immunotherapy in ovarian cancer.

Dr. O'Malley on the Optimal Use of PARP Inhibitors in Advanced Ovarian Cancer

March 10th 2020

David O’Malley, MD, professor, Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, and director, Division of Gynecologic Oncology at The Ohio State University Comprehensive Cancer Center–The James, discusses the optimal use of PARP inhibitors as frontline maintenance therapy in patients with advanced ovarian cancer.